Similar efficacy and safety of tenofovir in Asians and non-Asians with chronic hepatitis B

doi:10.3748/wjg.v21.i18.5524

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 18

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6371)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

392

WORD

185

HTML

3311

Figures (1-2)

216

Tables (1-3)

197

Sum=4301

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1018

Download

1052

Sum=2070

May 14, 2015 (publication date) through Dec 1, 2024

Times Cited of This Article

Times Cited (14)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. May 14, 2015; 21(18): 5524-5531
Published online May 14, 2015. doi: 10.3748/wjg.v21.i18.5524

Table 1 Patient characteristics at baseline n (%)

	HBeAg-negative		HBeAg-positive
	Asian	Non-Asian	Asian	Non-Asian
	n = 102	n = 186	n = 115	n = 113
Male	71 (70)	144 (77)	60 (52)^b	84 (73)
Age (yr, mean ± SD)	44 ± 9.4	44 ± 10.9	34 ± 9.7	33 ± 11.9
BMI (kg/m², mean ± SD)	24.1 ± 3.1^b	26.4 ± 4.5	23.0 ± 3.5^b	25.1 ± 5.5
HBV DNA (log₁₀ copies/mL, mean ± SD)	6.5 ± 1.4^a	6.9 ± 1.3	8.4 ± 1.1^b	8.9 ± 1.0
Median ALT, U/L (Q1, Q3)	73 (45, 115)	103 (67, 140)	90 (56, 144)	118 (88, 196)
Normal ALT¹	17 (17)^b	12 (6.5)	10 (9)	5 (4)

¹Normal ALT ≤ 34 U/L for females; ≤ 43 U/L for males.

^aP≤ 0.05,

^bP≤ 0.01, vs non-Asian patients. ALT: Alanine aminotransferase; BMI: Body mass index; HBeAg: Hepatitis B e antigen; HBV: Hepatitis B virus; Q1: Quartile 1; Q3: Quartile 3.

Citation: Pan CQ, Chan S, Trinh H, Yao A, Bae H, Lou L. Similar efficacy and safety of tenofovir in Asians and non-Asians with chronic hepatitis B. World J Gastroenterol 2015; 21(18): 5524-5531
URL: https://www.wjgnet.com/1007-9327/full/v21/i18/5524.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i18.5524